http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
혈관 운동 증상을 동반한 여성 갱년기 우울증 환자에서 Venlafaxine Hydrochloride Extended Release의 치료효과에 대한 개방 관찰 연구
김미루,이정구,백준형,김영훈 대한정신약물학회 2014 대한정신약물학회지 Vol.25 No.4
ObjectivezzDuring the transition to menopause, various symptoms including vasomotor symptoms and depressed mood lead to low quality of life. We investigated the effect of low-dose venlafaxine hydrochloride extended release on depressed mood and vasomotor symptoms of perimenopausal women. Methodszz33 perimenopausal women fulfilling Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria for a depressive episode were enrolled between January 2014 and May 2014. Subjects were prescribed 37.5 mg/day or 75 mg/day venlafaxine hydrochloride according to clinician’s judgement, and the dosages were maintained for 8 weeks. Depressed mood and other psychological difficulties were evaluated by using Hamilton Rating Scale for Depression (HAMD), Hamilton Rating Scale for Anxiety (HAMA), Clinical Global Impression-Severity. Climacteric symptoms including vasomotor symptoms were evaluated by using Greene Climacteric Scale (GCS). For statistical analysis, paired t-test was used. ResultszzSignificant decreases in HAMD, HAMA, GCS scores were observed after 2 weeks of treatment and the trends continued until the end of the study. The scores of HAMD significantly decreased, 28 of them reached remission (HAMD ≤7). The scores on vasomotor symptoms of GCS after 8 week treatment significantly decreased compared to baseline (13.1±5.0, p<0.01). ConclusionzzThese results suggest that venlafaxine hydrochloride is effective and tolerable treatment option for vasomotor symptoms and depressed mood in perimenopausal women. To validate our results, furthur studies with double-blind, placebo controlled will be needed. 본 연구는 갱년기 한국 여성의 우울 증상과 혈관 운동 증상에 있어 venlafaxine hydrochloride extended release의 치료 효과를 평가하였다. 혈관 운동 증상을 동반한 33명의 여성 갱년기 우울증 환자를 대상으로 37.5 mg/day, 75 mg/day 용량의 venlafaxine hydrochloride extended release를 8주간 투약하였다. HAMD, HAMA, CGI-S와 함께 갱년기 증상 평가 척도인 GCS를 통해 경과를 평가하였다. 본 연구 결과 venla-faxine hydrochloride는 8주 동안 HAMD 및 CGI, GCS를 포함한 전체 척도 점수에 있어 유의한 호전을 보였다. 33명의 대상자 중 1명이 심한 오심으로 중도 탈락했다. 이는 일반 갱년기 한국 여성의 우울 증상과 혈관 운동 증상의 치료에 있어 venlafaxine hydrochloride가 효과적인 치료안이 될 수 있다는 가능성을 보여준다. 본 연구 결과는 대조군 없이 진행된 개방 관찰 연구로 결과의 입증을 위한 장기간의 이중맹검 연구가 필요할 것이다.
Ali, Syed Mashhood,Koketsu, Mamoru,Asmat, Fahmeena Korean Chemical Society 2006 Bulletin of the Korean Chemical Society Vol.27 No.9
A detailed spectroscopic study ($^1H$ NMR, COSY, ROESY) of complexation of venlafaxine hydrochloride (VEN) with $\beta$-cyclodextrin ($\beta$--CD) was carried out in solution. The stoichiometry of the complex was determined to be 1 : 1 and penetration of aromatic ring into $\beta$-Cyclodextrin cavity was confirmed from primary rim side, with the help of ROESY spectral data. The structure of the venlafaxine hydrochloride-$\beta$-CD complex has been proposed. The association constant was determined to be 234 $M^{-1}$.
Syed Mashhood Ali*,Mamoru Koketsu,Fahmeena Asmat 대한화학회 2006 Bulletin of the Korean Chemical Society Vol.27 No.9
A detailed spectroscopic study (1H NMR, COSY, ROESY) of complexation of venlafaxine hydrochloride (VEN) with b-cyclodextrin (b-CD) was carried out in solution. The stoichiometry of the complex was determined to be 1 : 1 and penetration of aromatic ring into b-Cyclodextrin cavity was confirmed from primary rim side, with the help of ROESY spectral data. The structure of the venlafaxine hydrochloride-b-CD complex has been proposed. The association constant was determined to be 234 M-1.
Mehmet Akif Camkurt,Gizem Gülpamuk,Ebru Fındiklı,Rengin Elve 대한정신약물학회 2017 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.15 No.2
Venlafaxine is a serotonergic and noradrenergic reuptake inhibitor which is used for the treatment of depression. We report a case of galactorrhea in a patient with major depressive disorder after starting treatment with venlafaxine. In particular, we discuss the course of hyper and normoprolactinemic galactorrhea. We managed this side effect initially by dose reduction and further by switching to essitalopram. Physicians should be aware of endocrinologic side effects such as galactorrhea during the serotonin and noradrenaline reuptake inhibitor treatment.
Central Pontine Myelinolysis in a Normonatremic Patient with Depression
Yu Chia Liu,Yen Kuang Yang,Po See Chen,Wei Hung Chang 대한정신약물학회 2021 CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE Vol.19 No.3
A 76-year-old male presented with a recurrent depressive episode, an unsteady gait and cognitive impairment. Extensive blood tests, including hemogram, biochemical tests, folic acid, vitamin B12, and thyroid hormone, showed normal results. With the exception of the unsteady gait, neurological examination was negative. Brian magnetic resonance imaging (MRI) showed the typical feature of central pontine myelinolysis (CPM); however, there was no history of alcoholism, liver transplantation, malnutrition or rapid correction of hyponatremia. The patient had taken venlafaxine to treat major depressive disorder for more than 20 years. After discontinuation of venlafaxine, the unsteady gait gradually resolved, and subsequent MRI revealed reduction of the lesions over 6 months. We discuss herein the possible correlation between chronic use of venlafaxine and CPM.